ATHERO-B-CELL

Targeting and exploiting B cell functions for treatment in cardiovascular disease

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.atherobcell.eu/
Totale costo	7˙739˙594 €
EC contributo	5˙892˙178 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2018-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801	UK (OXFORD)	coordinator	1˙035˙840.00
2	ROCHE INNOVATION CENTER COPENHAGEN AS  Organization address address: FREMTIDSVEJ 3 city: Horsholm postcode: 2970 contact info Titolo: Dr. Nome: Henrik Cognome: ørum Email: send email Telefono: +45 45179800	DK (Horsholm)	participant	1˙020˙540.00
3	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Prof. Nome: François Cognome: Mach Email: send email Telefono: +41 223727190 Fax: +41 22 38 27 245	CH (GENEVE)	participant	531˙000.00
4	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Kamila Cognome: Kolasinska Email: send email Telefono: +44 2031083033 Fax: +44 20 78132849	UK (LONDON)	participant	526˙498.00
5	GENOWAY S.A.  Organization address address: Avenue Jean Jaures 181 city: LYON postcode: 69362 contact info Titolo: Dr. Nome: Angélique Cognome: Heckmann Email: send email Telefono: +33 0437654100	FR (LYON)	participant	492˙050.00
6	BERING LIMITED  Organization address address: PETERSHAM ROAD 36 city: RICHMOND postcode: TW10 6UW contact info Titolo: Dr. Nome: Ignat Cognome: Drozdov Email: send email Telefono: +44 7891552693	UK (RICHMOND)	participant	462˙500.00
7	LUNDS UNIVERSITET  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Dr. Nome: Jacqueline Cognome: Postma Email: send email Telefono: +46 40 39 12 36 Fax: +46 40 39 12 22	SE (LUND)	participant	441˙000.00
8	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Mrs. Nome: Karin Cognome: Krol Email: send email Telefono: +31 88 7551685	NL (UTRECHT)	participant	441˙000.00
9	UNIVERSITA DEGLI STUDI DI GENOVA  Organization address address: VIA BALBI 5 city: GENOVA postcode: 16126 contact info Titolo: Prof. Nome: Vincenzo Cognome: Savarino Email: send email Telefono: +39 0103538956 Fax: 390104000000	IT (GENOVA)	participant	405˙750.00
10	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Mrs. Nome: Caroline Cognome: Hamilton Email: send email Telefono: +46 8 517 759 59 Fax: +468 313147	SE (STOCKHOLM)	participant	366˙000.00
11	ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU  Organization address address: VIA FIORENTINA 151 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Cristiana Cognome: Tozzi Email: send email Telefono: +39 0577587906 Fax: 390578000000	IT (SIENA)	participant	170˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is getting stronger, raising hopes for novel therapeutic targets to be exploited clinically. Clinical evidence generated by the Academic partners of the Athero-B-Cell Consortium demonstrates that CVD is associated with pro- and anti-atherogenic B cell responses. We aim to use existing proteomic, transcriptomic and miRNA data generated from large-scale clinical studies in previous EU-funded collaborative efforts to decipher the pathways that favor pro- and anti-atherogenic B cell functions in order to unravel a new set of therapeutic targets and refine potential vaccine strategies for CVD. The selection and validation of targets will be made possible by substantial technological advance achieved by the participating SMEs that are world leaders in the field of bioinformatics, genetic modification including humanised mouse models, and 3rd generation antisense drugs with locked nucleic-acid (LNA) design that are in Phase II human trials. Academia-led innovation includes high-resolution methodologies such as CyTOF and ImageStream to interrogate available samples from clinical trials and the ability to validate the targets of interest in accredited models of CVD. The validation in vivo and in vitro of such targets will feed into the SME pipeline accelerating the process of drug discovery. The recent clinical success of 3rd generation antisense drugs underscores the advantage of the Athero-B-Cell approach: the seamless transition from validation tools to clinical applications. Harnessing protective or abating unwanted B cell responses has the potential to improve health, innovation and competitiveness of European SME and Academia, while shedding light on the pathogenesis of CVD, the world's biggest killer.'